Cadonilimab Combined With Gem/Cis as First Line Therapy in Patients With Advanced ICC

Phase 2

Active, not recruiting

• Conditions: Intrahepatic Cholangiocarcinoma
• Interventions: Drug: Cadonilimab+Gem/Cis

• Registration Number: NCT05781958
• Lead Sponsor: Shen Feng

Brief Summary

TOPAZ-1 phase III trail demonstrated that the addition of immune checkpoint inhibitor anti-PD-L1 antibody improved progression-free survival (PFS) and overall survival (OS) compared to Gem/Cis alone. Cadonilimab is a first-in-class bispecific, humanized IgG1 antibody targeting PD-1 and CTLA-4, which has the potential to boost immune surveillance in tumors. The goal of this clinical trial is to evaluated the efficacy and safety of cadonilimab combined with gemcitabine and cisplatin as first Line therapy in patients with advanced intrahepatic cholangiocarcinoma. Eligible participants will receive cadonilimab (up to 12 months) plus gemcitabine and cisplatin (for maximum of 6-8 cycles) until radiologic disease progression, unacceptable toxicity, or withdrawal from the study, whichever occurred first. The primary endpoint is objective response rate.

Detailed Description

Not available

Study Timeline

• Study Start: 2022-11-24
• Study First Submitted: 2023-02-20
• Study First Submitted QC: 2023-03-22
• Study First Posted: 2023-03-23
• Status Verified: 2023-10
• Last Update Submitted: 2023-10-31
• Last Update Posted: 2023-11-02
• Primary Completion: 2023-12-01
• Study Completion: 2024-12-01

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 64

Inclusion Criteria

1. Histologically or cytologically diagnosed intrahepatic cholangiocarcinoma (ICC)
2. At least 1 measurable lesion (according to RECIST1.1)
3. Have not previously received any systemic treatment
4. Age 18-75 years old, both male and female
5. ECOG performance status score (PS score) 0-2 point
6. Adequate medullary hematopoiesis function: Neutrophils≥1.5*10^9/L; platelets≥100*10^9/L
7. Adequate renal function: creatinine clearance > 60ml/min
8. Adequate hepatic function: Bilirubin ≤ 1.5 times the upper limit of normal
9. No cardiac insufficiency or chest pain (medically uncontrollable); no myocardial infarction in the 12 months prior to study initiation
10. Expectation survival time over 3 months
11. The patient must sign an informed consent form

Exclusion Criteria

1. History of another primary malignancy
2. Brain metastases or spinal cord compression
3. Uncontrolled intercurrent illness
4. Have active or previously recorded autoimmune or inflammatory diseases (eg Rheumatoid arthritis, psoriasis, systemic lupus erythematosus, AIDS, etc)
5. Have received allogeneic organ transplantation
6. Control of concurrent complications, including but not limited to persistent or active infections, symptomatic congestive heart failure, poorly controlled hypertension, unstable angina, poorly controlled arrhythmia, active interstitial lung disease ( ILD), severe chronic gastrointestinal disorders associated with diarrhea symptoms, may limit compliance with the psychiatric/social conditions required by the trial, and substantially increase the risk of adverse events or affect the ability of patients to sign written consent forms
7. History of active primary immunodeficiency
8. Pregnant or lactating women
9. Severe or uncontrolled infections
10. Patients with history of severe neurological or psychiatric illness, including dementia or epilepsy;
11. Patients with drug abuse, medical, psychological or social conditions that may interfere with the study results or the assessment of the study results;
12. Patients are unsuitable for the enrollment according to investigator's judgement.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Cadonilimab+Gem/Cis	Cadonilimab+Gem/Cis	-

Primary Outcome Measures

Name	Time	Method
Objective response rate (ORR) per RECIST 1.1	Up to two years	Defined as patients achieving a complete response \[CR\] or partial response \[PR\]

Secondary Outcome Measures

Name	Time	Method
Desease control rate (DCR) per RECIST 1.1	Up to two years	CR + PR + SD
Overall survival (OS)	Up to two years	Defined as the time from the start of treatment to the date of death from any cause
6mo PFS rate per RECIST 1.1	at 6 months	Progression-free survival (PFS) rate at 6 months
Progression free survival (PFS) per RECIST 1.1	Up to two years	Defined as the time from the start of treatment to the date of progressive disease, or death, whichever occurred first.
adverse events	Up to two years	Include Treatment emerge adverse events, treatment related adverse events and serious adverse events

Trial Locations

Locations (1)

Eastern hepatobilliary surgery hospital; 🇨🇳 Shanghai, Shanghai, China